Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma
详细信息 查看全文
- 作者：Dirk Schadendorfa ; dirk.schadendorf@uk-essen.de" class="auth_mail" title="E-mail the corresponding author ; Reinhard Dummerb ; Reinhard.Dummer@usz.ch" class="auth_mail" title="E-mail the corresponding author ; Axel Hauschildc ; ahauschild@dermatology.uni-kiel.de" class="auth_mail" title="E-mail the corresponding author ; Caroline Robertd ; Caroline.Robert@gustaveroussyr.fr" class="auth_mail" title="E-mail the corresponding author ; Omid Hamide ; ohamid@theangelesclinic.org" class="auth_mail" title="E-mail the corresponding author ; Adil Daudf ; Adil.Daud@ucsf.edu" class="auth_mail" title="E-mail the corresponding author ; Alfons van den Eertweghg ; vandeneertwegh@VUMC.nl" class="auth_mail" title="E-mail the corresponding author ; Lee Cranmerh ; lcranmer@uacc.arizona.edu" class="auth_mail" title="E-mail the corresponding author ; Steven O'Dayi ; stevenjoday@gmail.com" class="auth_mail" title="E-mail the corresponding author ; Igor Puzanovj ; igor.puzanov@vanderbilt.edu" class="auth_mail" title="E-mail the corresponding author ; Jacob Schachterk ; Jacob.Schachter@sheba.health.gov.il" class="auth_mail" title="E-mail the corresponding author ; Christian Blankl ; c.blank@nki.nl" class="auth_mail" title="E-mail the corresponding author ; April Salamam ; april.salama@duke.edu" class="auth_mail" title="E-mail the corresponding author ; Carmen Loquain ; carmen.loquai@unimedizin-mainz.de" class="auth_mail" title="E-mail the corresponding author ; Janice M. Mehnerto ; mehnerja@cinj.rutgers.edu" class="auth_mail" title="E-mail the corresponding author ; Darcy Hillep ; darcy_hille@merck.com" class="auth_mail" title="E-mail the corresponding author ; Scot Ebbinghausp ; scot_ebbinghaus@merck.com" class="auth_mail" title="E-mail the corresponding author ; S. Peter Kangp ; s.peter.kang@merck.com" class="auth_mail" title="E-mail the corresponding author ; Wei Zhoup ; wei.zhou2@merck.com" class="auth_mail" title="E-mail the corresponding author ; Antoni Ribasq ; aribas@mednet.ucla.edu" class="auth_mail" title="E-mail the corresponding author
- 关键词：Pembrolizumab ; Patient-reported outcomes ; Health-related quality of life ; KEYNOTE-002 ; Advanced melanoma ; Ipilimumab-refractory melanoma ; Chemotherapy ; EORTC QLQ-C30
- 刊名：European Journal of Cancer
- 出版年：2016
- 出版时间：November 2016
- 年：2016
- 卷：67
- 期：Complete
- 页码：46-54
- 全文大小：579 K
文摘
- •
Health-related quality of life (HRQoL) was evaluated in the KEYNOTE-002 study.
- •
HRQoL was maintained to a greater degree with pembrolizumab versus chemotherapy.
- •
In all arms, HRQoL decreased in patients who experienced disease progression.
- •
These data support pembrolizumab for ipilimumab-refractory advanced melanoma.